Skin toxicity associated with immune checkpoint inhibitors based on the FDA adverse event reporting system 2011 – 2023 data

Differences are present between ICI regimens in the pattern of skin toxicity with anti-PD-1 therapies exhibiting the highest incidence of skin toxicity and mortality rates, while anti-CTLA-4 therapies showed the most marked signals.